Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Men and women with metastatic advanced solid tumor cancer who:
Potential participants will be excluded who have:
To learn more about the study, call or email Pfizer Clinical Trial Contact Center, by phone:1-800-718-1021 or by email.
This study is looking at how well two cancer drugs work together to treat certain advanced cancers.
The researchers want to learn how safe and effective the combination of an immunotherapy (known as Avelumab) and a PARP inhibitor (known as Talazoparib) is for treating patients with locally advanced or metastatic solid tumors with a BRCA1, BRCA2, or ATM gene defect.
This is a single-arm, open-label study. This means that all patients in the study will receive the same treatments.